Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Recurrent or Metastatic HNSCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial
JAMA Oncol 2023 Apr 06;[EPub Ahead of Print], KJ Harrington, RL Ferris, M Gillison, M Tahara, A Argiris, J Fayette, M Schenker, Å Bratland, JWT Walker, P Grell, C Even, CH Chung, R Redman, A Coutte, S Salas, C Grant, S de Azevedo, D Soulières, AR Hansen, L Wei, TA Khan, K Miller-Moslin, M Roberts, R HaddadFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.